Sign in
Stories
Ethris Initiates Virus-Induced Asthma Treatment Study
Share
Advancements in Antibodies to Protect Im...
COVID Vaccines and Long COVID Link
COVID-19 Impact on Immunocompromised Pat...
CDC Revises COVID Guidelines
COVID Reporting Requirements Expire
COVID-19 Booster for Chinese New Year
Overview
API
Ethris GmbH has initiated the first-in-human dosing of ETH47, a lead candidate for the treatment of virus-induced asthma, in a Phase 1 study. The program has the potential to address pandemic preparedness against influenza and SARS-CoV-2. ETH47 aims to induce mucosal innate immune responses at viral entry sites with a virus- and mutation-independent mode of action. The Phase 1 clinical trial will evaluate safety, tolerability, pharmacokinetics, and target engagement, with funding from Bayern Innovativ and enrolling 88 healthy participants at a trial site in the UK.
Ask a question
How might ETH47's potential to address pandemic preparedness against influenza and SARS-CoV-2 impact global public health strategies?
In what ways could the success of ETH47 influence the future of mRNA-based therapies in the healthcare industry?
What are the potential implications of Ethris' technology platform for the development of new treatments for other respiratory diseases?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Sep 2023
Oct 2023
Nov 2023
Coverage